Therefore, the protective effect of HLA-B*40:01 and C*03:04 may also be explained by immune responses against neoantigens encoded by co-mutations that are enriched in NPM1-mutated DNMT3A-non-mutated AML. This evidence concerns the gene HLA-B and acute myeloid leukemia.